144 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 144 of 144 clinical reviews.
A head-to-head comparison of liraglutide and dulaglutide (Trulicity) covering cost, insurance access, dosing convenience, weight loss, cardiovascular outcomes, and switching protocols.
A clinical comparison of liraglutide and dulaglutide (Trulicity) covering weight loss, A1C reduction, cardiovascular outcomes, dosing, and cost. Evidence from SCALE, AWARD, and REWIND trials.
A clinical comparison of liraglutide and dulaglutide (Trulicity) side effects, tolerability, GI symptoms, injection-site reactions, and safety data from SCALE and REWIND trials.
A clinical guide to switching between liraglutide and dulaglutide (Trulicity), including dose equivalence, washout timing, side-effect management, and what the trial data actually shows for each GLP-1 receptor agonist.
A clinical comparison of Mounjaro (tirzepatide) and liraglutide covering efficacy, pricing, insurance coverage, and access pathways for weight loss and type 2 diabetes.
How does Mounjaro (tirzepatide) compare with liraglutide for weight loss and A1C reduction? A cross-trial efficacy analysis using SURPASS and SCALE data.
A clinical comparison of Mounjaro (tirzepatide) and liraglutide side effects, covering GI tolerability, pancreatitis risk, thyroid signals, and injection-site reactions based on each drug's FDA-approved labeling.
A clinical comparison of tirzepatide (Mounjaro) and liraglutide on weight loss, A1C reduction, dosing, and how to switch between them safely. prepared by the HealthRX.com Editorial Team.
Compare the side-effect profiles of Mounjaro (tirzepatide) and Rybelsus (oral semaglutide) using clinical trial data from SURPASS-2 and PIONEER programs.
A clinical comparison of Mounjaro (tirzepatide) and Rybelsus (oral semaglutide) covering efficacy, cost, insurance access, dosing, and who each drug suits best.
Compare tirzepatide (Mounjaro) and oral semaglutide (Rybelsus) for A1C reduction, weight loss, and clinical outcomes using SURPASS and PIONEER trial data.
There is no FDA conversion table for Mounjaro and Rybelsus. Compare indications, evidence limits, dosing constraints, and the information a prescriber needs to plan a switch.
A detailed clinical comparison of Mounjaro (tirzepatide) and Saxenda (liraglutide 3 mg) side-effect profiles, using trial data from SURPASS-2, SCALE, and supporting research to help patients and clinicians choose confidently.
A head-to-head comparison of Mounjaro (tirzepatide) and Saxenda (liraglutide 3 mg) covering weight-loss efficacy, pricing, insurance coverage, and access for 2026.
A clinical comparison of Mounjaro (tirzepatide) and Saxenda (liraglutide 3 mg) covering weight loss efficacy, A1C reduction, trial data, side effects, and switching guidance.
A clinical comparison of Mounjaro (tirzepatide) and Saxenda (liraglutide 3 mg) covering weight loss efficacy, mechanism differences, and how to switch safely between them.
A detailed side-effect comparison of Mounjaro (tirzepatide) and Trulicity (dulaglutide), including GI tolerability, hypoglycemia risk, cardiovascular safety, and discontinuation rates from SURPASS and REWIND trial data.
A clinical comparison of tirzepatide (Mounjaro) and dulaglutide (Trulicity) covering efficacy, cost, insurance coverage, prior authorization, and how to choose between them.
A clinical comparison of Mounjaro (tirzepatide) and Trulicity (dulaglutide) covering A1C reduction, weight loss, cardiovascular outcomes, and dosing across major trials.
A clinical comparison of Mounjaro (tirzepatide) and Trulicity (dulaglutide), including efficacy data from SURPASS and REWIND trials, and a step-by-step guide for switching between these GLP-1 medications.
The current Rybelsus label gives one limited Ozempic switch path, not a universal semaglutide conversion table. See which doses are covered and where recommendations are unavailable.
A detailed clinical comparison of semaglutide (Ozempic) and liraglutide side-effect profiles, using SUSTAIN-7, SCALE Obesity, and FDA labeling data to help patients and clinicians choose between these two GLP-1 receptor agonists.
A head-to-head comparison of Ozempic (semaglutide) and liraglutide covering cost, insurance access, clinical efficacy, and switching protocols for weight loss and type 2 diabetes.
A clinical comparison of Ozempic (semaglutide) and liraglutide for glycemic control and weight loss, with trial data from SUSTAIN-7, SCALE, and current prescribing guidelines.
A clinical guide to switching between Ozempic (semaglutide) and liraglutide, covering dose conversion, washout timing, side-effect management, and what trial data show about each drug's efficacy.
A clinical comparison of semaglutide (Ozempic) and tirzepatide (Mounjaro) side-effect profiles, drawing on SUSTAIN and SURPASS trial data, discontinuation rates, and GI tolerability.
A detailed comparison of Ozempic (semaglutide) and Mounjaro (tirzepatide) covering clinical efficacy, cost, insurance coverage, and switching protocols for patients and prescribers.
A clinical comparison of semaglutide (Ozempic) and tirzepatide (Mounjaro) for glycemic control and weight loss, with trial data from SUSTAIN and SURPASS programs.
A clinical comparison of Ozempic (semaglutide) and Mounjaro (tirzepatide), including trial data from SUSTAIN and SURPASS programs, and practical guidance on switching between the two GLP-1 medications.
A clinical comparison of Ozempic (injectable semaglutide) and Rybelsus (oral semaglutide) side-effect profiles, drawing on SUSTAIN and PIONEER trial data to help patients and prescribers choose between formulations.
A detailed clinical and cost comparison of Ozempic (injectable semaglutide) vs Rybelsus (oral semaglutide) covering efficacy, pricing, insurance access, and who should use which.
A clinical comparison of injectable semaglutide (Ozempic) and oral semaglutide (Rybelsus) covering A1C reduction, weight loss, trial data from SUSTAIN and PIONEER programs, and guidance on choosing between them.
A clinical comparison of semaglutide (Ozempic) vs liraglutide (Saxenda) for weight loss efficacy, dosing, side effects, and cost, with data from SUSTAIN-7, SCALE, and STEP trials.
Compare the side-effect profiles of Ozempic (semaglutide) and Saxenda (liraglutide 3 mg) across GI symptoms, pancreatitis risk, gallbladder events, and cardiovascular safety using clinical trial data.
A clinical comparison of Ozempic (semaglutide) and Saxenda (liraglutide) covering efficacy, cost, insurance coverage, and access for weight management and type 2 diabetes.
A clinical comparison of Ozempic (semaglutide) and Saxenda (liraglutide 3 mg), including trial data, dosing differences, and how to switch between them under medical supervision.
A clinical comparison of side-effect profiles between Ozempic (semaglutide) and Trulicity (dulaglutide), including GI tolerability, weight effects, cardiovascular outcomes, and switching protocols.
A clinical and financial comparison of semaglutide (Ozempic) and dulaglutide (Trulicity) covering efficacy data, insurance coverage, out-of-pocket costs, and switching protocols.
A clinical comparison of semaglutide (Ozempic) and dulaglutide (Trulicity) covering HbA1c reduction, weight loss, cardiovascular outcomes, dosing, side effects, and switching protocols.
A clinical comparison of semaglutide (Ozempic) and dulaglutide (Trulicity) covering efficacy, cardiovascular outcomes, dosing, side effects, and a step-by-step protocol for switching between them.
Primary-source review of adverse-event ascertainment and active-control design: study design, evidence limits, registry records, and current FDA status…
Primary-source review of adverse-event ascertainment and dosage-form context: study design, evidence limits, registry records, and current FDA status…
Primary-source review of adverse-event ascertainment and eligibility criteria: study design, evidence limits, registry records, and current FDA status…
Primary-source review of adverse-event ascertainment and follow-up duration: study design, evidence limits, registry records, and current FDA status…
Primary-source review of adverse-event ascertainment and indication alignment: study design, evidence limits, registry records, and current FDA status…
Primary-source review of adverse-event ascertainment and population selection: study design, evidence limits, registry records, and current FDA status…
Primary-source review of adverse-event ascertainment and regulatory-label context: study design, evidence limits, registry records, and current FDA…
Primary-source review of adverse-event ascertainment and route and schedule context: study design, evidence limits, registry records, and current FDA…
Primary-source review of endpoint interpretation and active-control design: study design, evidence limits, registry records, and current FDA status…
Primary-source review of endpoint interpretation and dosage-form context: study design, evidence limits, registry records, and current FDA status. Updated…
Primary-source review of endpoint interpretation and eligibility criteria: study design, evidence limits, registry records, and current FDA status…
Primary-source review of endpoint interpretation and follow-up duration: study design, evidence limits, registry records, and current FDA status. Updated…
Primary-source review of endpoint interpretation and indication alignment: study design, evidence limits, registry records, and current FDA status…
Primary-source review of endpoint interpretation and population selection: study design, evidence limits, registry records, and current FDA status…
Primary-source review of endpoint interpretation and regulatory-label context: study design, evidence limits, registry records, and current FDA status…
Primary-source review of endpoint interpretation and route and schedule context: study design, evidence limits, registry records, and current FDA status…
Primary-source review of market-status boundaries and active-control design: study design, evidence limits, registry records, and current FDA status…
Primary-source review of market-status boundaries and dosage-form context: study design, evidence limits, registry records, and current FDA status…
Primary-source review of market-status boundaries and eligibility criteria: study design, evidence limits, registry records, and current FDA status…
Primary-source review of market-status boundaries and follow-up duration: study design, evidence limits, registry records, and current FDA status. Updated…
Showing the first 60 matches. Use search or filters to narrow the library.